Haloperidol- and clozapine-induced enhancement of latent inhibition with extended conditioning: Implications for the mechanism of action of neuroleptic drugs

Neuropsychopharmacology

Volumn 16, Issue 1, 1997, Pages 42-50

  Weiner, I ^a   Shadach, E ^a   Barkai, R ^a   Feldon, J ^b  

^a TEL AVIV UNIVERSITY   (Israel)

^b ETH ZURICH   (Switzerland)

Author keywords

Latent inhibition; Neuroleptics; Rat; Switching

Indexed keywords

CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT;

ANIMAL EXPERIMENT; ARTICLE; CONDITIONING; DRUG MECHANISM; LATENT INHIBITION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0031014655     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(96)00145-5     Document Type: Article

References (68)

1. Anscombe F (1987): The disorder of consciousness in schizophrenia. Schizophr Bull 13:241-260
2. Baruch I, Hemsley D, Gray JA (1988): Differential performance of acute and chronic schizophrenics in a latent inhibition task. J Nerv Ment Dis 176:598-606
3. Bleuler E (1911): Dementia Praecox or the Group of Schizophrenias. New York, International Universities Press
4. Brier A, Buchanan RW, Kirkpatrick B (1994): Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am J Psychiatry 151:20-26
5. Broen WE (1968): Schizophrenia: Research and Theory. New York, Academic Press
6. Carpenter WT Jr, Heinrichs DW, Alphs LD (1985): Treatment of negative symptoms. Schizophr Bull 11:440-452
7. Carpenter WT Jr, Heinrichs DW, Wagman AMI (1988): Deficit and nondeficit forms of schizophrenia: The concept. Am J Psychiatry 145:578-583
8. Christison GW, Atwater GE, Dunn LA, Kilts CD (1988): Haloperidol enhancement of latent inhibition: Relation to therapeutic action? Biol Psychiatry 23:746-749
9. Cools A, Jaspers R, Schwartz M, Sontag KH, Vrijmoed de Vries M, Van den Bereken J (1984): Basal ganglia and switching motor programs. In McKenzie JS, Kemm RE, Wilcock N (eds), Basal Ganglia and Switching Motor Programs. New York, Plenum Press, pp 513-544
10. De la Casa LG, Ruiz G, Lubow RE (1993): Amphetamine-produced attenuation of latent inhibition is modulated by stimulus preexposure duration: Implications for schizophrenia. Biol Psychiatry 33:707-711
11. Dunn LA, Atwater GE, Kilts CD (1993): Effects of antipsychotic drugs on latent inhibition - Sensitivity and specificity of an animal behavioral model of clinical drug action. Psychopharmacology 112:315-323
12. Farde L, Nordstrom AL (1992): PET analysis indicates atypical central dopamine receptor occupancy in clozapinetreated patients. Br J Psychiatry 160:30-33
13. FeIdon J, Weiner I (1988): Long-term attentional deficit in nonhandled males: Possible involvement of the dopaminergic system. Psychopharmacology 95:231-236
14. Feldon J, Weiner I (1991): The latent inhibition model of schizophrenic attention disorder: Haloperidol and sulpiride enhance rats' ability to ignore irrelevant stimuli. Biol Psychiatry 29:635-646
15. Frith CD (1979): Consciousness, information processing and schizophrenia. Br J Psychiatry 134:225-235
16. Frith CD (1992): The Cognitive Neuropsychology of Schizophrenia. Hillsdale, NJ, Lawrence Erlbaum Associates Ltd
17. Gelissen M, Cools A (1988): Effect of intracaudate haloperidol and apomorphine on switching motor patterns upon current behavior of cats. Behav Brain Res 29:17-26
18. Gerlach J, Casey DE (1994): Drug treatment of schizophrenia: Myths and realities. Curr Opin Psychiatry 7:65-70
19. Gray JA, Feldon J, Rawlins JNP, Hemsley DR, Smith AD (1991): The neuropsychology of schizophrenia. Behav Brain Sci 14:1-84
20. Gray NS, Hemsley DR, Gray JA (1992a): Abolition of latent inhibition in acute, but not chronic, schizophrenics. Neurol Psychiatr Brain Res 1:83-89
21. Gray NS, Hemsley DR, Gray JA (1992b): Abolition of latent inhibition by a single low dose of amphetamine in man. Psychopharmacology 107:425-430
22. Hall G (1991): Perceptual and Associative Learning. New York, Oxford University Press
23. Kane JM, Freeman HL (1994): Towards more effective antipsychotic treatment. Br J Psychiatry 165:22-31
24. Kane JM, Marder SR (1993): Psychopharmacologic treatment of schizophrenia. Schizophr Bull 19:287-302
25. Karnath HO, Wallesch CW (1992): Inflexibility of mental planning - a characteristic disorder with prefrontal lobe lesions? Neuropsychologia 30:1011-1016
26. Killcross AS, Dickinson A, Robbins TW (1994a): Amphetamine-induced disruptions of latent inhibition are reinforcer mediated-Implications for animal models of schizophrenic attentional dysfunction. Psychopharmacology 115:185-195
27. Killcross AS, Dickinson A, Robbins TW (1994b): Effects of the neuroleptic alpha-flupenthixol on latent inhibition in aversively and appetitively motivated paradigms - Evidence for dopamine-reinforcer interactions. Psychopharmacology 115:196-205
28. Killcross AS, Robbins TW (1993): Differential effects of intraaccumbens and systemic amphetamine on latent inhibition using an on-baseline, within-subject conditioned suppression paradigm. Psychopharmacology 110:479-489
29. Lubow RE (1973): Latent inhibition. Psychol Bull 79:398-407
30. Lubow RE (1989): Latent Inhibition and Conditioned Attention Theory. New York, Cambridge University Press
31. Lubow RE, Gewirtz JC (1995): Latent inhibition in humans: Data, theory, and implications for schizophrenia. Psychol Bull 117:87-103
32. Lubow RE, Weiner I, Schnur P (1981): Conditioned attention theory. In Bower GH (ed), The Psychology of Learning and Motivation, vol 15. New York, Academic Press, pp 1-49
33. Lyon M (1991): Animal models of mania and schizophrenia. In Willner P (ed), Behavioral Models in Psychopharmacology: Theoretical, Industrial, and Clinical Perspectives. Cambridge, Cambridge University Press, pp 253-310
34. Mackintosh NJ (1975): A theory of attention: Variations in the associability of stimuli with reinforcement. Psychol Rev 82:276-298
35. Mackintosh NJ (1983): Conditioning and Associate Learning. New York: Oxford University Press
36. Magaro PA (1980): Cognition in Schizophrenia and Paranoia: The Integration of Cognitive Processes. Hillsdale, NJ, Lawrence Erlbaum
37. Meltzer HY (1989): Clinical studies on the mechanism of action of clozapine: The dopamine-serotonin hypothesis of schizophrenia. Psychopharmacology 99:S18-S27
38. Meltzer HY (1991): The mechanism of action of novel antipsychotic drugs. Schizophr Bull 17:263-287
39. Meltzer HY, Bastani B, Ramirez L, Matsubara S (1989a): Clozapine - New research on efficacy and mechanism of action. Eur Arch Psychiatr Neurol Sci 238:332-339
40. 2 affinities differentiate atypical and typical antipsychotic drugs. Psychopharmacol Bull 25:390-392
41. Moore JW, Stickney KJ (1980): Formation of attentional-associative networks in real time: Role of the hippocampus and implications for conditioning. Physiol Psychol 8:207-217
42. Mortimer AM (1994): Newer and older antipsychotics: A comparative review of appropriate use. CNS Drugs 2:381-396
43. Mortimer AM, McKenna PJ, Lund CE, Mannuzza S (1989): Rating of negative symptoms using the high evaluation of negativity (HEN) scale. Br J Psychiatry 155:89-91
44. Nutt DJ (1990): Specific anatomy, non-specific drugs: The present state of schizophrenia. J Psychopharmacol 4:171-175
45. Oades RD (1985): The role of noradrenaline in tuning and dopamine in switching between signals in the CNS. Neurosci Biobehav Rev 9:261-282
46. Payne RW (1966): The measurement and significance of overinclusive thinking and retardation in schizophrenic patients. In Hoch P, Zubin J (eds), Psychopathology of Schizophrenia. New York, Grune and Stratton
47. Peters SL, Joseph MH (1993): Haloperidol potentiation of latent inhibition in rats: Evidence for a critical role at conditioning rather than pre-exposure. Behav Pharmacol 4:183-186
48. Robbins TW (1991): Cognitive deficits in schizophrenia and Parkinson's disease - Neural basis and the role of dopamine. In Willner P, Scheel-Kruger J (eds), The Mesolimbic Dopamine System: From Motivation to Action. Chichester, UK, John Wiley & Sons Ltd
49. Robbins TW, Everitt BJ (1982): Functional studies of the central catecholamines. Int Rev Neurobiol 23:303-365
50. Schmajuk NA, Moore JW (1985): Real-time attentional models for classical conditioning and the hippocampus. Physiol Psychol 13:278-290
51. Schmajuk NA, Moore JW (1988): The hippocampus and the classically conditioned nictitating membrane response: A real-time attentional-associative model. Psychobiology 16:20-35
52. Shakow D (1962): Segmental set: A theory of the formal psychological deficit in schizophrenia. Arch Gen Psychiatry 6:17-33
53. Solomon PR, Crider A, Winkelman JW, Turi A, Kamer RM, Kaplan LJ (1981): Disrupted latent inhibition in the rat with chronic amphetamine or haloperidol-induced supersensitivity: Relationship to schizophrenic attention disorder. Biol Psychiatry 16:519-537
54. Spitzer M, Braun U, Hermle L, Maier S (1993): Associative semantic network dysfunction in thought-disordered schizophrenic patients - Direct evidence from indirect semantic priming. Biol Psychiatry 34:864-877
55. Swerdlow NR, Koob GF (1987): Dopamine, schizophrenia, mania and depression: Toward a unified hypothesis of cortico-striato-pallido-thalamic function. Behav Brain Res 10:215-217
56. Tandon R, Goldman R, DeQuardo JR, Goldman M, Perez M, Jibson M (1993): Positive and negative symptoms covary during clozapine treatment in schizophrenia. J Psychiatr Res 27:341-347
57. Tandon R, Kane JM (1993): Neuropharmacologic basis for clozapine's unique profile. Arch Gen Psychiatry 50:158-159
58. Van den Bos R, Cools AR (1989): The involvement of the nucleus accumbens in the ability of rats to switch to cuedirected behaviors. Life Sci 44:1697-1704
59. Warburton EC, Joseph MH, Feldon J, Weiner I, Gray JA (1994): Antagonism of amphetamine-induced disruption of latent inhibition in rats by haloperidol and ondansetron - Implications for a possible antipsychotic action of ondansetron. Psychopharmacology 114:657-664
60. Weiner I (1990): Neural substrates of latent inhibition: The switching model. Psychol Bull 108:442-161
61. Weiner I, Feldon J (1987): Facilitation of latent inhibition by haloperidol. Psychopharmacology 91:248-253
62. Weiner I, Feldon J (1994): The latent inhibition model of schizophrenic attention disorder and of antipsychotic drug action - Comment on Dunn, Atwater, and Kilts (Psychopharmacology 1993;112:315-323). Psychopharmacology 116:379-380
63. Weiner I, Feldon J, Katz Y (1987): Facilitation of the expression but not the acquisition of latent inhibition by haloperidol in rats. Pharmacol Biochem Behav 26:241-246
64. Weiner I, Lubow RE, Feldon J (1981): Chronic amphetamine and latent inhibition. Behav Brain Res 2:285-286
65. Weiner I, Lubow RE, Feldon J (1984): Abolition of the expression but not the acquisition of latent inhibition by chronic amphetamine in rats. Psychopharmacology 83:194-199
66. Weiner I, Lubow RE, Feldon J (1988): Disruption of latent inhibition by acute administration of low doses of amphetamine. Pharmacol Biochem Behav 30:871-878
67. Weiner I, Shadach E, Tarrasch R, Kidron R, Feldon J (in press): The latent inhibition model of schizophrenia: Further validation using the atypical neuroleptic, clozapine. Biol Psychiatry
68. Wolkin A, Sanfilipo M, Wolf AP, Angrist B, Brodie JD, Rotrosen J (1992): Negative symptoms and hypofrontality in chronic schizophrenia. Arch Gen Psychiatry 49:959-965